People

Ryan Mitteness

Counsel

Mitteness, Ryan

Ryan Mitteness has a general corporate practice, with a focus on capital markets transactions and public company corporate governance. Mr. Mitteness has experience representing issuers and underwriters in a wide variety of debt and equity offerings, including initial public offerings, follow-on equity offerings, high yield and investment grade debt offerings and private placements. Mr. Mitteness also advises public and private company clients on compliance with federal securities laws and corporate governance matters.

Prior to joining WilmerHale in 2014, Mr. Mitteness was an associate at Davis Polk & Wardwell LLP.

Publications & News

View

January 30, 2018

WilmerHale Represents Ocular Therapeutix™ in Public Offering of Common Stock

Ocular Therapeutix™, Inc. announced the closing of its underwritten public offering of 7,475,000 shares of its common stock at a public offering price of $5.00 per share.

January 26, 2018

WilmerHale Represents Spark Therapeutics in Licensing and Supply Agreement With Novartis

Spark Therapeutics, a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced it has entered into a licensing agreement with Novartis Pharmaceuticals to develop and commercialize investigational voretigene neparvovec outside the United States.

December 11, 2017

WilmerHale Represents Editas Medicine in $50M Offering of Common Stock

Editas Medicine, Inc., a leading genome editing company, announced the pricing of an underwritten offering of 1,970,000 shares of its common stock.

November 17, 2017

Legal Considerations in Pre-IPO Crossover Financings

In this article published by Bloomberg Law's Corporate Law & Accountability Report, authors Lia Der Marderosian and Ryan Mitteness explain that while late-stage crossover financings come with significant potential benefits to both the company and the investors, given the complexity of the legal issues involved, they must be structured and implemented carefully to avoid potential securities law violations, as well as to ensure that the company and investors are able to reap those anticipated benefits.

October 26, 2017

WilmerHale Serves as Counsel to Idera Pharmaceuticals in Public Offering of Common Stock

Idera Pharmaceuticals, Inc. announced the pricing of its underwritten public offering of 33,333,334 shares of its common stock at a public offering price of $1.50 per share.

July 27, 2017

WilmerHale Represents Kala Pharmaceuticals in $103.5 Million IPO

On July 25, 2017, Kala Pharmaceuticals, Inc. announced the closing of its initial public offering of 6,900,000 shares of common stock, including the underwriters' exercise in full of their option to purchase an additional 900,000 shares, at the public offering price of $15.00 per share.

January 27, 2017

Ocular Therapeutix Announces Public Offering of Common Stock

Ocular Therapeutix, Inc. announced the pricing of its registered underwritten public offering of 3,571,429 shares of its common stock.

December 28, 2016

WilmerHale Counsels Tokai Pharmaceuticals in Share Purchase Agreement with Otic Pharma

The WilmerHale deal team included Partners Hal Leibowitz, Stuart Falber, Belinda Juran, Bill Caporizzo and Amy Null; Counsel Michael Welhouse; Senior Associate Ryan Mitteness; and Associate Andrea Sorrentino.

December 15, 2016

WilmerHale Reps Spark Therapeutics in Licensing Agreement with Selecta Biosciences

Spark Therapeutics and Selecta Biosciences, Inc. announced a license agreement that provides Spark Therapeutics with exclusive worldwide rights to Selecta's proprietary Synthetic Vaccine Particles platform technology for co-administration with gene therapy targets.

September 22, 2016

WilmerHale Reps Eleven Biotherapeutics in Acquisition of Viventia Bio

The acquisition creates a NASDAQ-listed company focused on the development of novel therapies based upon antibody fragments genetically fused to cytotoxic proteins, or targeted protein therapeutics, as new treatments in areas of oncology with significant unmet need.

Practices

Skip Navigation Links.

Education

HBX | Harvard Business School, Credential of Readiness (CORe), Business Analytics, Financial Accounting, Economics for Managers, with Honors, 2016

JD, with highest honors, George Washington University Law School, 2010, Order of the Coif, Articles Editor, The George Washington Law Review

BA, cum laude, Washington and Lee University, 2007

Bar Admissions

District of Columbia

New York

Skip Navigation Links.